Summit Therapeutics Inc. - Common Stock (SMMT)

Many investors see this nuclear power company as a possible answer to the growing energy needs from artificial intelligence, and it has benefited from that.

They haven't peaked yet.

The healthcare stock could skyrocket if ivonescimab obtains approval from regulators, but there's still plenty of risk here.

This biotech company is rolling the dice with a planned regulatory submission.

There's still time to get in on these rising stars.

Summit SMMT Q3 2025 Earnings Call Transcript

The company's prospects improve with every clinical win.

Join us as we dissect Summit Therapeutics' potential in the biotech sector. Can their promising drug Ansuvimab overcome the odds, or is this stock a risky bet?

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.

Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.

Summit Therapeutics reported a wider-than-expected Q3 2025 loss but is advancing its lead drug, ivonescimab, toward a key FDA submission.

This biotech company was relatively unknown a few years ago.

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom, showcasing the power and volatility of high-growth companies in a rapidly recovering market environment. 

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended ditching Opendoor: "We don't want to be in a meme stock."

Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biotech trial updates and mixed analyst calls pressured others.